FDA approves Roche’s giredestrant combination for advanced breast cancer
The FDA approved Roche’s giredestrant combination for ESR1-mutated advanced breast cancer.
The FDA approved Roche’s giredestrant combination for ESR1-mutated advanced breast cancer.